Navigation Links
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
Date:11/7/2007

tigator. "Anti-TNF therapies have dramatically advanced our approach to the management of this disease, and these data demonstrate the potential of golimumab as a new efficacious anti-TNF-alpha treatment option."

According to findings from the Golimumab - A Randomized Study in Ankylosing Spondylitis Subjects of a Novel Anti-TNF mAB Injection (SC) Given Every Four Weeks (GO-RAISE) trial, 59 percent of patients receiving golimumab 50 mg and 60 percent of patients receiving golimumab 100 mg achieved the primary endpoint of the study, ASAS 20 at week 14, compared with 22 percent of patients receiving placebo (P < 0.001 for both comparisons). Clinical benefit was demonstrated as early as week four after one dose and was maintained through week 24. At six months, 56 percent of patients receiving golimumab 50 mg and 66 percent of patients receiving golimumab 100 mg achieved ASAS 20 compared with 23 percent of patients receiving placebo (P < 0.001 for both comparisons). Furthermore, at six months, 44 percent of patients receiving golimumab 50 mg and 54 percent of patients receiving golimumab 100 mg achieved ASAS 40, defined as 40 percent improvement in ankylosing spondylitis signs and symptoms, compared with 15 percent of patients receiving placebo (P < 0.001 for both comparisons).

Importantly, at six months, 51 percent of patients receiving golimumab 50 mg and 48 percent of patients receiving golimumab 100 mg achieved a 50 percent reduction in disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50), a standard measure for assessing ankylosing spondylitis disease activity, compared with 15 percent of patients receiving placebo (P < 0.001). The BASDAI measures important markers of disease activity, including pain, morning stiffness and joint swelling.

"When treating this potentially progressive and debilitating disease, we attempt to reduce pain and other symptoms so that patients can maintain or improve physical f
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
7. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
8. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... fourth quarter and full year ended December 31, 2014. ... PTC. We are now a growing commercial-stage biopharma company, ... rare disease space," stated Stuart W. Peltz, Ph.D., Chief ... bring the first treatment for Duchenne muscular dystrophy to ...
(Date:2/27/2015)... , Feb. 27, 2015  Chiasma, Inc., a ... product for the orphan condition acromegaly, today announced the ... Participants in the financing included new investors Rock Springs ... public investment fund, as well as existing investors MPM ... ARCH Venture Partners. Chiasma intends to ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... April 18, 2012 Financial executives in the medical ... and the burden of its related compliance costs will ... according to a survey conducted by KPMG LLP, the ... said their companies are already contemplating actions such as ...
... organiser UBM Live has revealed further details of ... CPhI Southeast Asia (SEA) 2012. Set to debut from 10-12 ... SEA is the first trade show and exhibition of its ... the ASEAN region. CPhI SEA will provide ...
Cached Medicine Technology:KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3
(Date:2/27/2015)... Nashville, TN (PRWEB) February 27, 2015 ... Oral Health, has announced a scholarship for rising freshmen ... is Nashville’s leading periodontist office specializing in many periodontal ... , and treatment of gum disease . In ... single $1,000 college scholarship for eligible rising freshmen undergraduate ...
(Date:2/27/2015)... Insight Accelerator Labs has partnered ... development of an in-line urine flow meter platform ... developed in direct response to current high cost ... error margins with potentially grave consequences. The company’s ... provide trending data analysis to signal ICU caregivers ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Mirena IUD ... women who allegedly suffered uterine perforations and other serious ... device continue to move forward in the multicounty litigation ... Liebhard LLP reports. Court records indicate that the ... 24th, following a Conference convened that same day. (In ...
(Date:2/27/2015)... 2015 Over 440,000 patients die annually as ... of two jumbo jet airplanes crashing each day. Now more ... in an effort to do all they can to stay ... Carmona, the 17th U.S. Surgeon General, discusses the importance of ... able to address safety issues to ensure that all our ...
(Date:2/27/2015)... York, NY (PRWEB) February 27, 2015 Ticket ... Tickets for his "Forest Hills Drive Tour Act 3: ... album "2014 Forest Hills Drive" which debuted on the charts ... hip-hop album. In March, this accomplished hip-hop artist will ... in early March and will visit cities such as San ...
Breaking Medicine News(10 mins):Health News:Nashville Periodontist Office AIOH Announces 2015 Scholarship 2Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Progress in New Jersey with Issuance of New Case Management Order, Bernstein Liebhard LLP Reports 3Health News:Dr. Richard Carmona, the 17th U.S. Surgeon General, and IntelliCentrics Raise Awareness in Mediaplanet’s “Patient Safety” Campaign 2Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 2Health News:J. Cole Tickets in Los Angeles, Mountain View, Chula Vista, New York, Chicago, Indianapolis, Holmdel, Dallas, Seattle, Camden, Bristow, Atlanta, Houston & Detroit On Sale 3
... myeloma patients are better equipped to halt progression of this ... stem cell transplant, according to a study co-authored by a ... Institute. The study, published in the New England ... the risk of progressive myeloma or death for the stem ...
... 15 (HealthDay News) -- Researchers have identified gene variants ... say their findings could help identify patients who would ... the University of California-Los Angeles, say their findings also ... disease is a progressive movement disorder marked by tremor, ...
... , TUESDAY, May 15 (HealthDay News) -- Asthma ... million adults (8.2 percent) suffering from the disorder in 2010, ... for Disease Control and Prevention. The CDC analysis also ... adults have been diagnosed with the illness at some point ...
... DETROIT An increasingly common and safer type of surgery ... for older, sicker and poorer patients who are uninsured or ... to a new study by researchers at Henry Ford Hospital. ... the diseased portion of a cancerous kidney, leaving the unaffected ...
... prostate cancer patients may not be getting the same ... first-of-its-kind study by researchers at Henry Ford Hospital who ... remove diseased prostates. While it is possible that ... results of radical prostatectomy are not as good for ...
... Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ... Challenges Explorations winner, an initiative funded by the Bill ... Ph.D., FAAP, LA BioMed lead investigator and Professor of ... and development research project, titled "Aerosol Delivery of Synthetic ...
Cached Medicine News:Health News:Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant 2Health News:Genes Might Be Key to Parkinson's Spread 2Health News:Asthma Cases Continue to Rise in U.S., Affecting Millions 2Health News:Asthma Cases Continue to Rise in U.S., Affecting Millions 3Health News:Safer kidney cancer surgery under-used for poorer, sicker Medicare, Medicaid patients 2Health News:Quality of care, other issues may cause worse results in black prostate cancer surgery patients 2Health News:LA BioMed receives Grand Challenges Explorations grant 2
Cold light source dual outlet....
... The 4150S is a state ... halogen light source with an ... standard coupler to connect optical ... source distinguishes itself from all ...
With the LX300, you don't have to compromise the quality of your lighting system to meet your budget needs. You get the best and whitest light possible from an affordable 300 Watt light source....
... and most versatile light source Luxtec offers. ... this unique light source allows to use ... instrument or two UltraLite Headlights at the ... white light that is as close to ...
Medicine Products: